Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer : 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

収録刊行物

• Lancet Oncol.

  Lancet Oncol. 2009